The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Maria-Victoria Mateos | ESH MM 2018 | Recent results of clinical trials in SMM
Featured:
María-Victoria Mateos4th International Conference on Multiple Myeloma, European School of Haematology, 5–7 October, Mandelieu, France
At ESH 2018, Professor Maria-Victoria Mateos spoke to the MM Hub about clinical trial results in smoldering multiple myeloma (SMM). Professor Mateos explained most of these trials are focused on the high-risk subgroup who are symptomatic, who have a risk of progression of 50% at 2-years. The first trial in this setting was almost 9 years ago (as of 2018). It was a phase III trial investigating lenalidomide and dexamethasone versus no treatment in 120 patients with high-risk SMM. Treatment with len+dex was effective in delaying progression and also gave an OS benefit with low toxicity. When this video was recorded, there were 55 trials ongoing in this population, some with an objective to delay progression and others with an aim of curing.
Recent results of clinical trials in SMM